These renowned companies will become your audience at China [email protected] Hamburg! Don’t miss out the last 10 days to apply for a slot and pitch your innovations in front of top-tier and investors.
Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007. Founded in 1992, Fosun operates three business lines, in Health, Happiness and Wealth, creating world-class products and services for families around the world. In 2018, Fosun recorded revenues of RMB 109.4 billion (c.US$ 16.5 billion) with total assets worth RMB 681.51 billion (c.US$ 99.13 billion) as of 30 June 2019.
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. Yiling pharma sticks to the principle of taking TCM academic development to impetus industrialization, taking technology as the forerunner, market as the guide, and built operational “Five in One” mode as integrating scientific research, clinical practices, production, marketing and teaching together. Yiling products involve TCM, health care products, western formulations, and TCM slices, etc. It owns the modern production line for capsule, soft capsule, tablet, granule, liquid injection, etc. By now, Yiling products have been exported to South Korea, Vietnam, England, Canada, Netherlands, Singapore, Russia and so on.
CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicine to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline with a strategic emphasis on immune-oncology combination therapies. Currently, 5 late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model, and substantial funding, CStone’s vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Apollobio is dedicated to developing and commercializing cutting-edge innovative oncology drugs to address the unmet medical needs of cancer patients in China.
Established in 2016, with our headquarter in Beijing, the company has assembled a team of experts in product development, regulation and healthcare access to enable effective collaboration with external partners. With such a strategic approach and a focus on oncology, the company has now successfully built an oncology pipeline for two Stage 3 and one pre-clinical drug candidates. Alongside our current drug candidates, the team is continuously searching for innovative, first-in-class, differentiated cancer drugs globally, with a number of potential partnerships under negotiation.